A pharmacist-led program to discontinue duplicate incretin therapy with glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for diabetes can optimize therapy and save more than $7,500 per beneficiary, a new study has found.
The two agents are commonly used in the management of type 2 diabetes, said Nicholas Friedlander, PharmD, a pharmacist at Prime Therapeutics/Magellan Rx Management. However, both drug classes exert antidiabetic effects through